Company / Depreciation & Amortization
Enliven Therapeutics, Inc. Depreciation & Amortization History
FY2019-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$300.0K
FY2024
5-year range
$97.0K / $300.0K
FY2020-FY2024
Trend
+0.0%
vs FY2023
Sector context
#143 of 163
Health Care
What the data says
Enliven Therapeutics, Inc.'s depreciation & amortization of $300,000 is lower than 88% of companies in the Health Care sector (FY2024). Increased from $200,000 to $300,000 over the past 2 years.
Based on SEC 10-K filings.
$300,000 in FY2024 with a 5-year CAGR of +55.5%.
Increased from $200,000 to $300,000 over the past 2 years.
Health Care sector context is included.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- +44.7%
- 5-Year CAGR
- +55.5%
- 10-Year CAGR
- -
Sector benchmark
Top 12% in Health CareTop 12% of 163This company $300.0K Sector average $219.4M
▼
-99.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +55.5%, indicating consistent growth.
- In FY2024, depreciation & amortization increased 0.0% year-over-year.
- Ranks #143 out of 163 companies in the Health Care sector.
- Lowest depreciation & amortization in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 7.84 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $300.0K | +0.0% |
| FY2023 | $300.0K | +50.0% |
| FY2022 | $200.0K | +102.0% |
| FY2021 | $99.0K | +2.1% |
| FY2020 | $97.0K | +193.9% |
| FY2019 | $33.0K | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026